Taken together, these results suggest that the combination of gefitinib and BYL719 has a synergistic therapeutic effect on PI3K activation NSCLC by inhibiting phosphorylation of AKT in vivo. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.